Singapore approves Neurophet's AI brain degeneration analysis software

South Korean company, Neruophet has received medical device approval from the Singapore's Health Science Authority for its AI-enabled degenerative brain disease diagnosis assistant software. 

The image analysis software, Neurophet AQUA, analyses magnetic resonance images (MRI) with AI technology to analyse brain atrophy and white matter damages found in neurodegenerative disease such as Alzheimer's disease and vascular dementia. The company claims the software can segment and analyse brain MRI scans in under 5 minutes with a high analysis success rate. The product is compatible with MRI device manufacturers such as GE, Philips, and Canon. 

Neurophet first entered the market with its flagship product, Neurophet Scale PET, a product which quantitatively analyses biomarkers of Alzheimer's disease by combining brain PET and MRI images. The company plans to now jointly advance the two products to continue improving diagnosis for Alzheimer's disease globally.  

"With the approval of two of our flagship products in Singapore, we are beginning to penetrate the South East Asian market," Neurophet CEO Jun-kil Been said.